524661 WELCURE

Welcure Drugs & Pharmaceuticals Share Price

₹11.75 +0.4 (3.52%)

19 May, 2025 03:07

SIP TrendupStart SIP in WELCURE

Start SIP

Performance

  • Low
  • ₹11
  • High
  • ₹12
  • 52 Week Low
  • ₹4
  • 52 Week High
  • ₹16
  • Open Price₹12
  • Previous Close₹11
  • Volume95,476

Investment Returns

  • Over 1 Month + 40.21%
  • Over 3 Month + 33.52%
  • Over 6 Month + 45.6%
  • Over 1 Year + 128.16%
SIP Lightning

Smart Investing Starts Here Start SIP with Welcure Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Welcure Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 70
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 132
  • P/B Ratio
  • 1.3
  • Average True Range
  • 0.59
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.46
  • RSI
  • 78.82
  • MFI
  • 92.21

Welcure Drugs & Pharmaceuticals Financials

Welcure Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹11.75
+ 0.4 (3.52%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹9.96
  • 50 Day
  • ₹9.35
  • 100 Day
  • ₹8.98
  • 200 Day
  • ₹8.07

Resistance and Support

11.55 Pivot Speed
  • R3 12.91
  • R2 12.40
  • R1 12.06
  • S1 11.21
  • S2 10.70
  • S3 10.36

What's your outlook on Welcure Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Welcure Drugs & Pharms. has an operating revenue of Rs. 33.52 Cr. on a trailing 12-month basis. An annual revenue de-growth of -63% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -12% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 27% and 45% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 108 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Welcure Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-14 Others Inter-alia, to consider 1. Appointment of Managing Director. 2. Alteration in Main Objects Clause of MOA. 3 .Increase in the Authorized Share Capital of the Company. 4. Other business matters.
2025-02-14 Quarterly Results
2024-11-14 Quarterly Results (Revised)
2024-10-21 Others
2024-08-14 Quarterly Results

Welcure Drugs & Pharmaceuticals F&O

Welcure Drugs & Pharmaceuticals Shareholding Pattern

0%
98.99%
1.01%

About Welcure Drugs & Pharmaceuticals

  • NSE Symbol
  • WELCURE
  • BSE Symbol
  • 524661
  • Managing Director & CFO
  • Mr. Altaf Hussain Shah
  • ISIN
  • INE331C01017

Similar Stocks to Welcure Drugs & Pharmaceuticals

Welcure Drugs & Pharmaceuticals FAQs

Welcure Drugs & Pharmaceuticals share price is ₹11 As on 19 May, 2025 | 02:53

The Market Cap of Welcure Drugs & Pharmaceuticals is ₹132.2 Cr As on 19 May, 2025 | 02:53

The P/E ratio of Welcure Drugs & Pharmaceuticals is 70 As on 19 May, 2025 | 02:53

The PB ratio of Welcure Drugs & Pharmaceuticals is 1.3 As on 19 May, 2025 | 02:53

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23